


Please type a plus sign (+) inside this box → ☐



PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/036,542	
				Filing Date	January 7, 2002	
				First Named Inventor	Birse et al.	
				Group Art Unit	1646	
				Examiner Name	Mertz, P.	
Attorney Docket Number	PA002P1					
Sheet	1	of	1			

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
PM	AA	WO	99/62939	A1	Tisdale, M.J. and Todorov, P.T.	12-09-1999	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
PM	AB	GENESEQ Accession No. AAY07773, Human Genome Sciences, Inc., "Human secreted protein fragment encoded from gene 30," (February 1999).
	AC	PIR Accession No. A54175, "zinc-alpha-2-glycoprotein precursor - human," (September 1994).
	AD	SWISS-PROT Accession No. P25311, "ZA2G_HUMAN," (May 1992).
	AE	ARAKI, T. <i>et al.</i> , "Complete amino acid sequence of human plasma Zn- α_2 -glycoprotein and its homology to histocompatibility antigens," <i>P.N.A.S.</i> 85:679-683 (February 1998).
	AF	FREIJE, JP <i>et al.</i> , "Human Zn-alpha 2-glycoprotein cDNA cloning and expression analysis in benign and malignant breast tissues," <i>FEBS Lett.</i> 290(1-2):247-249 (September 1991) (Abstract).
	AG	FREIJE, JP <i>et al.</i> , "Human Zn-alpha 2-glycoprotein: complete genomic sequence, identification of a related pseudogene and relationship to class I major histocompatibility complex genes," <i>Genomics</i> 18(3):575-587 (December 1993) (Abstract).
	AH	SÁNCHEZ, L.M. <i>et al.</i> , "Biochemical characterization and crystalization of human Zn- α_2 -glycoprotein, a soluble class I major histocompatibility complex homolog," <i>P.N.A.S.</i> 94:4626-4630 (April 1997).
	AI	UEYAMA, H. <i>et al.</i> , "Cloning and nucleotide sequence of a human Zn-alpha 2-glycoprotein cDNA and chromosomal assignment of its gene," <i>Biochem. Biophys. Res. Comm.</i> 177(2):696-703 (June 1991) (Abstract).
	AJ	UEYAMA, H. <i>et al.</i> , "Molecular cloning and chromosomal assignment of the gene for human Zn-alpha 2-glycoprotein," <i>Biochemistry</i> 32(48):12968-12976 (December 1993) (Abstract).

Examiner Signature	<i>Penna Mertz</i>	Date Considered	5/24/04
--------------------	--------------------	-----------------	---------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.